Head-to-head comparisons of medication uses, side effects, warnings, and more.
Rinvoq (upadacitinib)
Cimzia (certolizumab)
Rinvoq (upadacitinib)
Cimzia (certolizumab)
Summary of Rinvoq vs. Cimzia
Summary for JAK inhibitor
Prescription only
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. It's used to treat certain inflammatory conditions, such as rheumatoid arthritis (RA), ulcerative colitis (UC), and eczema (atopic dermatitis). But it's not a first-choice option and typically only prescribed when other treatments haven't worked well. Rinvoq (upadacitinib) is taken by mouth, usually once daily. It's available as an extended-release tablet (Rinvoq) and an oral solution (Rinvoq LQ), but the two formulations aren't interchangeable. Side effects include a higher risk of infections, acne, and nausea.
Summary for TNF blocker
Prescription only
Cimzia (certolizumab) is an injection that's used to treat many autoimmune conditions, such as rheumatoid arthritis, psoriasis, and Crohn's disease. This medication is given every 2 to 4 weeks. It can be used by itself or together with other medications, such as methotrexate. Side effects of Cimzia (certolizumab) include upper respiratory infections, urinary tract infections, and skin rash.
Indications of Rinvoq vs. Cimzia
Indications for
Moderate-to-severe inflammatory conditions in which other treatments haven't worked: